Retatrutide, by Soma Pharmaceuticals , is gaining significant attention as a potential therapy for metabolic management . This innovative compound integrates the mechanism of a GLP-1 receptor stimulant and a GIP receptor agonist , aiming to simply promote metabolic improvements but also target associated metabolic issues . Early patient studies hav